BDABF Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationPositive operating and free cash flow in the TTM period marks a meaningful recovery from 2025 weakness and several earlier negative periods. This provides internally generated funding for operations and investment, although continued consistency will determine how durable the improvement becomes.
Operating Profitability RecoveryThe return to positive operating profit shows that the core business has recovered substantially from the deep 2024 loss. Maintaining an operating margin in the mid-single-digit range would support reinvestment and improve resilience, even though bottom-line profitability has not yet returned.
Recurring Consumables ModelInstrument placements can create an installed base that supports recurring demand for reagents, controls, calibrators, and other supplies. This combination of upfront analyzer sales and replenishing consumables gives Boule a structurally repeatable revenue stream beyond individual instrument purchases.
Bears Say
Declining RevenueRevenue remains in decline despite the improvement from the 2024 collapse, indicating that demand and market expansion have not yet stabilized. A sustained top-line contraction can reduce operating leverage, limit investment capacity, and make the recent profitability recovery harder to maintain.
Higher Financial LeverageThe sharp increase in leverage has weakened Boule’s balance-sheet flexibility and raises the financial burden if earnings remain uneven. With equity also below earlier levels, the company has less capacity to absorb operating setbacks or fund future growth without relying more heavily on debt.
Persistent Net LossesOperating recovery has not yet translated into sustained net profitability, as Boule still reported small losses in both the latest twelve-month period and 2025. Continued net losses can constrain equity growth, weaken shareholder returns, and reduce the durability of cash generation over time.
Boule Diagnostics AB News
BDABF FAQ
What was Boule Diagnostics AB’s price range in the past 12 months?
Currently, no data Available
What is Boule Diagnostics AB’s market cap?
Boule Diagnostics AB’s market cap is $12.40M.
When is Boule Diagnostics AB’s upcoming earnings report date?
Boule Diagnostics AB’s upcoming earnings report date is Oct 23, 2026 which is in 42 days.
How were Boule Diagnostics AB’s earnings last quarter?
Boule Diagnostics AB released its earnings results on Jul 17, 2026. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of $0.001 by -$0.006.
Is Boule Diagnostics AB overvalued?
According to Wall Street analysts Boule Diagnostics AB’s price is currently Undervalued.
Does Boule Diagnostics AB pay dividends?
Boule Diagnostics AB does not currently pay dividends.
What is Boule Diagnostics AB’s EPS estimate?
Boule Diagnostics AB’s EPS estimate is >-0.01.
How many shares outstanding does Boule Diagnostics AB have?
Boule Diagnostics AB has 38,833,103 shares outstanding.
What happened to Boule Diagnostics AB’s price movement after its last earnings report?
Boule Diagnostics AB reported an EPS of -$0.005 in its last earnings report, missing expectations of $0.001. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Boule Diagnostics AB?
Currently, no hedge funds are holding shares in BDABF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms. The company was founded in 1956 and is headquartered in Spånga, Sweden.